Mylan Hungary Kft, Pharmaceutical Import Profile — Hungary (DGFT 2022–2026)

Name: Mylan Hungary Kft, Pharmaceutical Import Records from India — 14 Products, $23.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Hungary Kft, — Pharmaceutical Importer Profile (2026) | 14 Products, $23.9M Trade | TransData Nexus

Mylan Hungary Kft,

Pharmaceutical Importer · Hungary · Cardiovascular Focus · $23.9M Total Trade · DGFT Verified

Mylan Hungary Kft, is a pharmaceutical importer based in Hungary with a total trade value of $23.9M across 14 products in 6 therapeutic categories. Based on 507 verified import shipments from Indian Customs (DGFT) records, Mylan Hungary Kft, is the #1 buyer in 6 products including Simvastatin, Enalapril, Gliclazide. Mylan Hungary Kft, sources from 3 verified Indian suppliers, with Mylan Laboratories Limited accounting for 99.6% of imports.

Mylan Hungary Kft, — Import Portfolio & Supplier Network

Mylan Hungary Kft, import network — 14 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Hungary Kft,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$31.2M	902	99.6%
Unichem Laboratories Limited	$99.0K	2	0.3%
Intas Pharmaceuticals Limited

What Formulations Does Mylan Hungary Kft, Import?

Formulation	Value	Ships
Harmless medicines, ibuprofen tablets	$946.0K	20
Harmless medicines, ibuprofen lysine TAB	$900.0K	18
Valsartan and hydrochlorothiazide	$690.7K	18
Harmless medicines, ibuprofen lysine tab684mg (eu)	$662.9K	15
Propafenone hydrochloride film coated	$564.3K	13
Pantoprazole sodium delayed-release	$502.5K	11
Harmless medicines, pantoprazole	$435.5K	11
Ibuprofen tablets 400 MG	$429.3K	9
Harmless medicines, simvastatin	$427.9K	10
Harmless medicines, propafenone	$400.0K	8
Pantoprazole sodium delayed release	$400.0K	8
Harmless medicines, ciprofloxacin	$357.4K	9
Harmless medicines, duloxetine hard	$350.0K	7
Ibuprofen lysine tablets 684MG	$350.0K	7
Harmless medicines, telmisartan	$340.7K	8

Mylan Hungary Kft, imports 371 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 14 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ibuprofen	Analgesics & Antipyretics	$6.0M	120	1.0%	8
2	Valsartan	Cardiovascular	$4.5M	90	2.3%	7
3	Simvastatin	Cardiovascular	$2.7M	54	1.5%	1
4	Pantoprazole	Gastrointestinal	$2.4M	47	0.2%	15
5	Telmisartan	Cardiovascular	$1.9M	37	0.0%	2
6	Fenofibrate	Lipid & Metabolism	$1.3M	25	1.7%	2
7	Enalapril	Cardiovascular	$1.1M	23	0.5%	1
8	Gliclazide	Advanced Diabetes Medications	$1.1M	21	0.3%	1
9	Pravastatin	Cardiovascular	$856.5K	26	1.6%	1
10	Amlodipine	Cardiovascular	$850.0K	17	0.0%	3
11	Bisoprolol	Cardiovascular	$578.6K	31	0.7%	17
12	Atovaquone	Antimalarial & Antiparasitic	$350.0K	7	0.0%	1
13	Irbesartan	Cardiovascular	$250.0K	5	0.2%	13
14	Proguanil	Antimalarial & Antiparasitic	$200.0K	4	0.0%	1

Mylan Hungary Kft, imports 14 pharmaceutical products across 6 categories into Hungary totaling $23.9M. The company is the #1 buyer for 6 products: Simvastatin, Enalapril, Gliclazide, Pravastatin, Atovaquone.

Mylan Hungary Kft, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Hungary Kft. is a pharmaceutical importer and buyer based in Komárom, Hungary. Established on June 14, 2010, the company operates as a subsidiary of Viatris, a global healthcare entity formed in 2020 through the merger of Mylan N.V. and Upjohn, Pfizer's off-patent medicine division. Mylan Hungary Kft. specializes in the marketing, sales, and distribution of generic and specialty medicines across various therapeutic areas within Hungary. The company's strategic focus emphasizes enhancing access to medicines, expanding its portfolio, and ensuring a reliable pharmaceutical supply chain.

2Distribution Network

Mylan Hungary Kft. operates a centralized distribution model from its headquarters in Komárom, Hungary. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's extensive import activities suggest a well-established infrastructure capable of managing a diverse product portfolio. The distribution network primarily serves the Hungarian market, ensuring the availability of a wide range of pharmaceutical products to meet local healthcare needs.

3Industry Role

As a pharmaceutical importer and buyer, Mylan Hungary Kft. plays a pivotal role in Hungary's pharmaceutical supply chain. The company sources a variety of finished pharmaceutical formulations from international suppliers, including a significant volume from India. By importing and distributing these products, Mylan Hungary Kft. ensures the availability of essential medications across Hungary, thereby contributing to the country's healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Hungary Kft,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Hungary Kft. demonstrates a high degree of sourcing concentration, with a substantial portion of its imports originating from a single supplier, Mylan Laboratories Limited. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and potential regulatory changes affecting the supplier. The company's reliance on a single supplier indicates a strategic choice to maintain consistency and quality in its product offerings. However, the limited supplier base may also impact the company's ability to negotiate favorable terms and diversify its product range.

2Supply Chain Resilience

The resilience of Mylan Hungary Kft.'s Indian supply chain is influenced by its reliance on a single supplier, Mylan Laboratories Limited. This dependency may expose the company to risks such as supply disruptions, regulatory changes, and geopolitical factors affecting trade relations. The lack of backup suppliers and limited formulation diversity further heightens these risks. To enhance supply chain resilience, Mylan Hungary Kft. could consider diversifying its supplier base and incorporating a broader range of formulations to mitigate potential disruptions.

3Strategic Implications

Importing Pharmaceuticals into Hungary — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Hungary

1Regulatory Authority & Framework

In Hungary, the National Institute of Pharmacy and Nutrition (OGYÉI) serves as the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharmaceutical imports includes the Act XCV of 2005 on Medicinal Products and the Government Decree 44/2005 (IV. 5.) on the Detailed Rules of Medicinal Products. The marketing authorization pathway for Indian generics involves obtaining approval from OGYÉI, which includes submitting a dossier demonstrating the product's quality, safety, and efficacy, as well as compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Hungary necessitate that importers hold a valid wholesale distribution authorization issued by OGYÉI. Additionally, imported products must be accompanied by a GMP certificate recognized by the European Union, WHO, or PIC/S. This ensures that the manufacturing processes meet international quality standards, thereby safeguarding public health.

3Quality & Labeling

Mylan Hungary Kft, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Hungary Kft.'s product category focus on cardiovascular, analgesics & antipyretics, and gastrointestinal medications aligns with prevalent health concerns in Hungary. The significant import volumes in these therapeutic areas indicate strong market demand and the company's strategic emphasis on addressing critical health issues. This focus enables Mylan Hungary Kft. to cater effectively to the therapeutic needs of the Hungarian population.

2Sourcing Profile

Mylan Hungary Kft. primarily sources generic pharmaceutical products, with a notable emphasis on formulations such as Simvastatin, Enalapril, Gliclazide, Pravastatin, Atovaquone, and Proguanil. India plays a crucial role in the company's procurement strategy, serving as a key supplier for these formulations. The company's sourcing strategy reflects a commitment to providing cost-effective and essential medications to the Hungarian market.

3Market Positioning

Based on its product mix, Mylan Hungary Kft. serves multiple segments of the Hungarian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse product portfolio enables it to meet the needs of various healthcare providers and patients, thereby strengthening its position in the market.

Seller's Guide — How to Become a Supplier to Mylan Hungary Kft,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Mylan Hungary Kft. by offering alternative products or formulations that align with the company's therapeutic focus. Identifying gaps in Mylan Hungary Kft.'s current sourcing, such as underrepresented therapeutic areas or formulations, can provide avenues for new suppliers to enter the market. Establishing relationships with Mylan Hungary Kft. can lead to mutually beneficial partnerships and expanded market reach.

2Requirements & Qualifications

Indian exporters seeking to supply Mylan Hungary Kft. and the Hungarian market must obtain a wholesale distribution authorization from OGYÉI. Additionally, products must be accompanied by a GMP certificate recognized by the European Union, WHO, or PIC/S. Compliance with Hungarian labeling requirements, including the use of the Hungarian language and adherence to serialization mandates, is also essential.

3How to Approach

Frequently Asked Questions — Mylan Hungary Kft,

What products does Mylan Hungary Kft, import from India?

Mylan Hungary Kft, imports 14 pharmaceutical products across 6 categories. Top imports: Ibuprofen ($6.0M), Valsartan ($4.5M), Simvastatin ($2.7M), Pantoprazole ($2.4M), Telmisartan ($1.9M).

Who supplies pharmaceuticals to Mylan Hungary Kft, from India?

Mylan Hungary Kft, sources from 3 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (99.6% of imports, $31.2M).

What is Mylan Hungary Kft,'s total pharmaceutical import value?

Mylan Hungary Kft,'s total pharmaceutical import value from India is $23.9M, based on 507 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Hungary Kft, focus on?

Mylan Hungary Kft, imports across 6 categories. The largest: Cardiovascular (53.2%), Analgesics & Antipyretics (25.1%), Gastrointestinal (9.8%).

Get Full Mylan Hungary Kft, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.